Endocrinology

Bhatt leads discussion on a new AHA statement regarding one of the most advancing fields of cardiovascular care.

Patients with TED might be particularly vulnerable to COVID-19 infections.

A discussion about a recent scientific statement outlining the treatment of coronary artery disease in type 2 diabetics from the AHA with statement co-author Deepak Bhatt, MD.

Jacquelyn Center, PhD, discuss with HCPLive the findings of her study and factors that increase mortality risk.

The findings provide insight into practice, provide a rubric for future studies, and suggest areas to improve resource use and patient care.

Investigators compare cesarean delivery to vaginal delivery to understand the association between delivery type and obesity and type 2 diabetes.

Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.

A new scientific statement from the AHA offers guidance to clinicians tasked with treating CAD in patients with type 2 diabetes.

A conversation on new AI software which can identify a five-fold greater rate of potential fractures.

Results of a new study dive deeper into the impact of preoperative metformin use in diabetics.

Endocrinologists make can a difference in COVID-19 by restricting their use of glucocorticoids.  According to an editorial published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism, patients treated with glucocorticoids will be at higher risk for coronavirus disease 2019 (COVID-19), the infection caused by the novel coronavirus. 

Patrick Campbell sat down  with Paul Stewart, MD, Executive Dean of the Faculty of Medicine and Health at University of Leeds and editor in chief of the Journal of Clinical Endocrinology & Metabolism to discuss why endocrinologists are expressing additional concern for their patients during the COVID-19 outbreak.

Discussing the impact of the ongoing outbreak on endocrinology practices and endocrinologists with the Executive Dean of the Faculty of Medicine and Health at University of Leeds.

Discussing an editorial in the Journal of Clinical Endocrinology & Metabolism with journal editor in chief Paul Stewart, MD.

A new perspective from federal and institutional experts explains the cause of disease severity and mortality in older, cardiovascular-risk patients.

A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.

There is a growing understanding that obesity and non-alcoholic fatty liver disease are related.

Currently, guidelines call for liver biopsies to diagnose NASH disease in patients.

Bout moderate-to-vigorous physical activity does not increase as much in very poor fitness groups.

The findings can lead to more education on the risk of thyroid immune-related adverse event.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

An analysis shows that patients find desiccated thyroid extract to be more effective and improve patient outcomes better than other therapies.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

African American and Hispanic patients use devices for type 1 diabetes less than Caucasian patients.

Study from ENDO 2020 assesses the effects of teprotumumab based on the age, gender, and smoking status of patients.

Appropriate monitoring and treatment of hypothyroidism is needed for individuals who work long hours.

New data from ENDO 2020 suggests the presence of erectile dysfunction and sexual symptoms was linked to increased risk of death.

Treating thyrotropin changes associated with aging adaptation could adversely alter key homeostatic compensations.

Glucagon-like receptor agonists did not reduce the rate of hospitalization for heart failure as much as SGLT2 inhibitors did.

Patients with fractures closer to the center of the body had a 1.5- to four-fold greater risk of death over 2 years of follow-up.